We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

106 hedge funds and large institutions have $186M invested in Cymabay Therapeutics in 2022 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 32 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $801K | Put options by funds: $345K

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

6% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 32

10% less funds holding

Funds holding: 118 → 106 (-12)

13% less capital invested

Capital invested by funds: $213M → $186M (-$27.1M)

29% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 28

Holders
106
Holders Change
-12
Holders Change %
-10.17%
% of All Funds
1.79%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
20
Increased
30
Reduced
32
Closed
28
Calls
$801K
Puts
$345K
Net Calls
+$456K
Net Calls Change
+$107K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$3.76M
2
LCM
Lynx1 Capital Management
Puerto Rico
+$2.87M
3
NCM
Nantahala Capital Management
Connecticut
+$1.79M
4
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$1.71M
5
Millennium Management
Millennium Management
New York
+$1.54M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$8.39M
2
JP Morgan Chase
JP Morgan Chase
New York
-$3.11M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.39M
4
State Street
State Street
Massachusetts
-$2.38M
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.44M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
51
Algert Global
California
$288K +$118K +49,600 +103%
RJA
52
Raymond James & Associates
Florida
$262K -$21.2K -8,892 -9%
GCP
53
GSA Capital Partners
United Kingdom
$183K -$311K -130,050 -68%
BAAM
54
Baker Avenue Asset Management
California
$156K – – –
LPL Financial
55
LPL Financial
California
$151K +$2.76K +1,155 +2%
CSS
56
Cubist Systematic Strategies
Connecticut
$151K +$42.2K +17,654 +52%
Charles Schwab
57
Charles Schwab
California
$144K -$455K -190,603 -80%
CSPIA
58
Cary Street Partners Investment Advisory
Virginia
$118K +$23.9K +10,000 +33%
XT
59
XTX Topco
Cayman Islands
$102K +$41.5K +17,380 +101%
Acadian Asset Management
60
Acadian Asset Management
Massachusetts
$94K +$76K +31,827 New
LP
61
LMR Partners
United Kingdom
$90K +$72.5K +30,360 New
MAMU
62
Myriad Asset Management US
Florida
$89K +$71.7K +30,000 New
CM
63
Caption Management
Oklahoma
$88K +$47.8K +20,000 +200%
Bank of New York Mellon
64
Bank of New York Mellon
New York
$86K -$592K -247,630 -89%
Rafferty Asset Management
65
Rafferty Asset Management
New York
$82K +$9K +3,768 +16%
MMA
66
Miracle Mile Advisors
California
$74K – – –
First Manhattan
67
First Manhattan
New York
$73K – – –
Franklin Resources
68
Franklin Resources
California
$72K -$2.36K -988 -4%
YIH
69
Y-Intercept (HK)
Hong Kong
$70K +$56.5K +23,644 New
Ameriprise
70
Ameriprise
Minnesota
$66K -$3.34K -1,400 -6%
Qube Research & Technologies (QRT)
71
Qube Research & Technologies (QRT)
United Kingdom
$54K +$43.4K +18,162 New
JIC
72
Johnson Investment Counsel
Ohio
$53K – – –
Verition Fund Management
73
Verition Fund Management
Connecticut
$47K +$37.7K +15,800 New
Bank of Nova Scotia
74
Bank of Nova Scotia
Ontario, Canada
$46K -$2.23K -932 -6%
CHAM
75
Clear Harbor Asset Management
Connecticut
$46K +$11.9K +5,000 +47%
1 2
3
4 5

CBAY Hedge Fund Activity: Q2 2022 in Review

106 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2022, worth a combined $186M — down 13% from $213M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of CBAY and 20 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 30 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $3.76M. The largest seller was BlackRock, cutting an estimated $8.39M.

  • 106 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2022, down from 118 in Q1 2022.
  • Funds reported $186M of Cymabay Therapeutics stock for Q2 2022, down 13% quarter-over-quarter.
  • 20 funds opened new Cymabay Therapeutics positions in Q2 2022 and 28 closed out, a net change of -8 holders.
  • The largest Cymabay Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $3.76M added.
  • The largest Cymabay Therapeutics seller in Q2 2022 was BlackRock, an estimated $8.39M sold.

Based on aggregated 13F filings for Q2 2022.